Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2023 | 67 | 2.140 |
Why?
|
| Staphylococcal Infections | 6 | 2023 | 67 | 2.010 |
Why?
|
| Rotavirus Vaccines | 6 | 2016 | 14 | 1.690 |
Why?
|
| Community-Acquired Infections | 4 | 2023 | 22 | 1.620 |
Why?
|
| Rotavirus Infections | 5 | 2016 | 17 | 1.560 |
Why?
|
| Gastroenteritis | 4 | 2016 | 18 | 1.460 |
Why?
|
| Carrier State | 2 | 2017 | 33 | 0.890 |
Why?
|
| Masks | 1 | 2023 | 16 | 0.780 |
Why?
|
| Georgia | 9 | 2023 | 192 | 0.770 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 432 | 0.750 |
Why?
|
| Antibodies, Neutralizing | 4 | 2026 | 127 | 0.690 |
Why?
|
| Rotavirus | 3 | 2016 | 14 | 0.640 |
Why?
|
| Antibodies, Viral | 4 | 2026 | 306 | 0.620 |
Why?
|
| Pediatrics | 2 | 2013 | 70 | 0.620 |
Why?
|
| Child | 14 | 2023 | 3443 | 0.600 |
Why?
|
| Infant | 11 | 2021 | 1175 | 0.600 |
Why?
|
| Staphylococcus aureus | 5 | 2023 | 94 | 0.600 |
Why?
|
| Staphylococcal Skin Infections | 2 | 2017 | 10 | 0.550 |
Why?
|
| Electronic Health Records | 1 | 2019 | 108 | 0.540 |
Why?
|
| Soft Tissue Infections | 1 | 2017 | 6 | 0.520 |
Why?
|
| Child, Preschool | 10 | 2023 | 1546 | 0.480 |
Why?
|
| Vaccination | 2 | 2016 | 355 | 0.440 |
Why?
|
| Humans | 35 | 2026 | 43102 | 0.430 |
Why?
|
| Health Personnel | 2 | 2013 | 277 | 0.370 |
Why?
|
| Ambulatory Care | 1 | 2013 | 81 | 0.370 |
Why?
|
| Lead Poisoning | 2 | 2023 | 25 | 0.360 |
Why?
|
| Health Status Disparities | 3 | 2023 | 719 | 0.360 |
Why?
|
| Information Systems | 1 | 2011 | 14 | 0.360 |
Why?
|
| Medicaid | 3 | 2020 | 143 | 0.340 |
Why?
|
| Lead | 2 | 2023 | 100 | 0.340 |
Why?
|
| Retrospective Studies | 6 | 2024 | 2544 | 0.320 |
Why?
|
| Case-Control Studies | 5 | 2017 | 1285 | 0.310 |
Why?
|
| Male | 19 | 2026 | 23409 | 0.310 |
Why?
|
| Female | 19 | 2026 | 24698 | 0.300 |
Why?
|
| Infant, Newborn | 4 | 2024 | 972 | 0.300 |
Why?
|
| Methicillin Resistance | 2 | 2007 | 12 | 0.290 |
Why?
|
| Abscess | 2 | 2017 | 10 | 0.250 |
Why?
|
| Emergency Service, Hospital | 4 | 2020 | 278 | 0.240 |
Why?
|
| Hospitals, Pediatric | 2 | 2024 | 22 | 0.240 |
Why?
|
| United States | 8 | 2026 | 5205 | 0.240 |
Why?
|
| Feces | 2 | 2016 | 132 | 0.230 |
Why?
|
| Syphilis, Congenital | 1 | 2024 | 2 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 375 | 0.200 |
Why?
|
| Methicillin | 1 | 2023 | 4 | 0.200 |
Why?
|
| Immunization, Secondary | 4 | 2026 | 16 | 0.200 |
Why?
|
| Research Design | 1 | 2025 | 385 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2024 | 117 | 0.190 |
Why?
|
| Prevalence | 4 | 2017 | 1612 | 0.190 |
Why?
|
| Interleukin-10 | 1 | 2021 | 87 | 0.170 |
Why?
|
| Asthma | 2 | 2016 | 416 | 0.170 |
Why?
|
| Schools | 1 | 2023 | 283 | 0.170 |
Why?
|
| AIDS Serodiagnosis | 1 | 2000 | 25 | 0.160 |
Why?
|
| Specialization | 1 | 2020 | 26 | 0.160 |
Why?
|
| Mass Screening | 2 | 2021 | 541 | 0.150 |
Why?
|
| Chlamydia Infections | 1 | 2020 | 200 | 0.140 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 1998 | 12 | 0.140 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 236 | 0.140 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 4 | 0.130 |
Why?
|
| Herpesvirus 1, Human | 1 | 1998 | 64 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 166 | 0.130 |
Why?
|
| Clindamycin | 1 | 2017 | 13 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2019 | 246 | 0.130 |
Why?
|
| Virus Shedding | 1 | 2016 | 9 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 245 | 0.130 |
Why?
|
| Circovirus | 1 | 2016 | 12 | 0.130 |
Why?
|
| Adult | 8 | 2026 | 13872 | 0.120 |
Why?
|
| Mediastinal Diseases | 1 | 1996 | 1 | 0.120 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 44 | 0.120 |
Why?
|
| Cross Protection | 1 | 2015 | 5 | 0.120 |
Why?
|
| Incidence | 1 | 2019 | 1078 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2019 | 363 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2016 | 321 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2016 | 311 | 0.110 |
Why?
|
| Vaccines, Synthetic | 2 | 2025 | 80 | 0.110 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2013 | 27 | 0.110 |
Why?
|
| Vaccines, Combined | 2 | 2023 | 12 | 0.100 |
Why?
|
| Diarrhea, Infantile | 1 | 2013 | 5 | 0.100 |
Why?
|
| Connecticut | 1 | 2011 | 11 | 0.090 |
Why?
|
| Pregnancy | 3 | 2024 | 1772 | 0.090 |
Why?
|
| Minnesota | 1 | 2011 | 41 | 0.090 |
Why?
|
| Risk Factors | 3 | 2017 | 3994 | 0.090 |
Why?
|
| Vaccines, Attenuated | 3 | 2016 | 75 | 0.080 |
Why?
|
| Neurons | 1 | 1998 | 1263 | 0.080 |
Why?
|
| Adolescent | 2 | 2019 | 6081 | 0.080 |
Why?
|
| Genotype | 1 | 2013 | 800 | 0.080 |
Why?
|
| Middle Aged | 4 | 2026 | 12222 | 0.080 |
Why?
|
| Small-Area Analysis | 2 | 2016 | 10 | 0.060 |
Why?
|
| HIV Infections | 1 | 2000 | 2586 | 0.060 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2024 | 7 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2023 | 36 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2019 | 1600 | 0.050 |
Why?
|
| Succinimides | 1 | 2023 | 12 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2026 | 1180 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 719 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3156 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2021 | 15 | 0.050 |
Why?
|
| Linear Models | 1 | 2023 | 317 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2021 | 69 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 40 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 1234 | 0.040 |
Why?
|
| Pregnancy, Ectopic | 1 | 2020 | 15 | 0.040 |
Why?
|
| Photoperiod | 1 | 2020 | 27 | 0.040 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2020 | 19 | 0.040 |
Why?
|
| Chicago | 1 | 2000 | 31 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 224 | 0.040 |
Why?
|
| Chlamydia | 1 | 2020 | 45 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 239 | 0.040 |
Why?
|
| Probability | 1 | 2000 | 82 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2000 | 49 | 0.040 |
Why?
|
| Chlamydia muridarum | 1 | 2020 | 104 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2021 | 321 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2000 | 74 | 0.040 |
Why?
|
| Poverty | 1 | 2023 | 400 | 0.040 |
Why?
|
| Gas Gangrene | 1 | 1999 | 1 | 0.040 |
Why?
|
| Clostridium perfringens | 1 | 1999 | 4 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2023 | 1271 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 179 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 256 | 0.040 |
Why?
|
| Chondroitin ABC Lyase | 1 | 1998 | 2 | 0.040 |
Why?
|
| Polysaccharide-Lyases | 1 | 1998 | 10 | 0.040 |
Why?
|
| Galactosides | 1 | 1998 | 11 | 0.030 |
Why?
|
| Chick Embryo | 1 | 1998 | 79 | 0.030 |
Why?
|
| Heparin | 1 | 1998 | 40 | 0.030 |
Why?
|
| Epithelium | 1 | 1998 | 78 | 0.030 |
Why?
|
| Vero Cells | 1 | 1998 | 112 | 0.030 |
Why?
|
| Urban Population | 1 | 2000 | 374 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 678 | 0.030 |
Why?
|
| Texas | 1 | 2020 | 457 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 14 | 0.030 |
Why?
|
| Drainage | 1 | 2017 | 12 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 1998 | 91 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 173 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 508 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 437 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 317 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2016 | 22 | 0.030 |
Why?
|
| Indoles | 1 | 1998 | 187 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1998 | 281 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2020 | 380 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 758 | 0.030 |
Why?
|
| Astrocytes | 1 | 1998 | 244 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 224 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 249 | 0.030 |
Why?
|
| Air Pollution | 1 | 2016 | 87 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2000 | 497 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 1869 | 0.030 |
Why?
|
| Diarrhea | 1 | 2015 | 95 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 245 | 0.030 |
Why?
|
| Utilization Review | 1 | 2013 | 17 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 162 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 50 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 1857 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 16992 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 6644 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1604 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1999 | 48 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1999 | 26 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1998 | 91 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1998 | 206 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 455 | 0.010 |
Why?
|
| Pain | 1 | 1999 | 290 | 0.010 |
Why?
|
| Hospitalization | 1 | 1998 | 485 | 0.010 |
Why?
|